Cargando…

Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh

BACKGROUND: Bangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease and affect the attempts to curb transmission of drug resistant tubercul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rifat, Mahfuza, Hall, John, Oldmeadow, Christopher, Husain, Ashaque, Milton, Abul Hasnat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647619/
https://www.ncbi.nlm.nih.gov/pubmed/26573825
http://dx.doi.org/10.1186/s12879-015-1253-9
_version_ 1782401139142033408
author Rifat, Mahfuza
Hall, John
Oldmeadow, Christopher
Husain, Ashaque
Milton, Abul Hasnat
author_facet Rifat, Mahfuza
Hall, John
Oldmeadow, Christopher
Husain, Ashaque
Milton, Abul Hasnat
author_sort Rifat, Mahfuza
collection PubMed
description BACKGROUND: Bangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease and affect the attempts to curb transmission of drug resistant tuberculosis. The main objective of this study was to investigate the health system delay in multidrug resistant tuberculosis treatment in Bangladesh and to explore the factors related to the delay. METHODS: Information related to the delay was collected as part of a previously conducted case–control study. The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). Information was collected by face-to-face interviews and through record reviews from all three Government hospitals providing multidrug resistant tuberculosis services, from September 2012 to April 2013. Multivariable regression analysis was performed using Bootstrap variance estimators. Definitions were as follows: Provider delay: time between visiting a provider for first consultation on MDR-TB related symptom to visiting a designated diagnostic centre for testing; Diagnostic delay: time from date of diagnostic sample provided to date of result; Treatment initiation delay: time between the date of diagnosis and date of treatment initiation; Health system delay: time between visiting a provider to start of treatment. Health system delay was derived by adding provider delay, diagnostic delay and treatment initiation delay. RESULTS: The 207 multidrug resistant tuberculosis patients experienced a health system delay of median 7.1 weeks. The health system delay consists of provider delay (median 4 weeks), diagnostic delay (median 5 days) and treatment initiation delay (median 10 days). Health system delay (Coefficient: 37.7; 95 %; CI 15.0–60.4; p 0.003) was associated with the visit to private practitioners for first consultation. CONCLUSIONS: Diagnosis time for multidrug resistant tuberculosis was fast using the rapid tests. However, some degree of delay was present in treatment initiation, after diagnosis. The most effective way to reduce health system delay would be through strategies such as engaging private practitioners in multidrug resistant tuberculosis control.
format Online
Article
Text
id pubmed-4647619
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46476192015-11-18 Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh Rifat, Mahfuza Hall, John Oldmeadow, Christopher Husain, Ashaque Milton, Abul Hasnat BMC Infect Dis Research Article BACKGROUND: Bangladesh is one of the 27 high burden countries for multidrug resistant tuberculosis listed by the World Health Organization. Delay in multidrug resistant tuberculosis treatment may allow progression of the disease and affect the attempts to curb transmission of drug resistant tuberculosis. The main objective of this study was to investigate the health system delay in multidrug resistant tuberculosis treatment in Bangladesh and to explore the factors related to the delay. METHODS: Information related to the delay was collected as part of a previously conducted case–control study. The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). Information was collected by face-to-face interviews and through record reviews from all three Government hospitals providing multidrug resistant tuberculosis services, from September 2012 to April 2013. Multivariable regression analysis was performed using Bootstrap variance estimators. Definitions were as follows: Provider delay: time between visiting a provider for first consultation on MDR-TB related symptom to visiting a designated diagnostic centre for testing; Diagnostic delay: time from date of diagnostic sample provided to date of result; Treatment initiation delay: time between the date of diagnosis and date of treatment initiation; Health system delay: time between visiting a provider to start of treatment. Health system delay was derived by adding provider delay, diagnostic delay and treatment initiation delay. RESULTS: The 207 multidrug resistant tuberculosis patients experienced a health system delay of median 7.1 weeks. The health system delay consists of provider delay (median 4 weeks), diagnostic delay (median 5 days) and treatment initiation delay (median 10 days). Health system delay (Coefficient: 37.7; 95 %; CI 15.0–60.4; p 0.003) was associated with the visit to private practitioners for first consultation. CONCLUSIONS: Diagnosis time for multidrug resistant tuberculosis was fast using the rapid tests. However, some degree of delay was present in treatment initiation, after diagnosis. The most effective way to reduce health system delay would be through strategies such as engaging private practitioners in multidrug resistant tuberculosis control. BioMed Central 2015-11-16 /pmc/articles/PMC4647619/ /pubmed/26573825 http://dx.doi.org/10.1186/s12879-015-1253-9 Text en © Rifat et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rifat, Mahfuza
Hall, John
Oldmeadow, Christopher
Husain, Ashaque
Milton, Abul Hasnat
Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title_full Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title_fullStr Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title_full_unstemmed Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title_short Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh
title_sort health system delay in treatment of multidrug resistant tuberculosis patients in bangladesh
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647619/
https://www.ncbi.nlm.nih.gov/pubmed/26573825
http://dx.doi.org/10.1186/s12879-015-1253-9
work_keys_str_mv AT rifatmahfuza healthsystemdelayintreatmentofmultidrugresistanttuberculosispatientsinbangladesh
AT halljohn healthsystemdelayintreatmentofmultidrugresistanttuberculosispatientsinbangladesh
AT oldmeadowchristopher healthsystemdelayintreatmentofmultidrugresistanttuberculosispatientsinbangladesh
AT husainashaque healthsystemdelayintreatmentofmultidrugresistanttuberculosispatientsinbangladesh
AT miltonabulhasnat healthsystemdelayintreatmentofmultidrugresistanttuberculosispatientsinbangladesh